Russia’s Cancer Vaccine “Enteromix” Shows 100% Response in Early Trials
Russia’s new vaccine Enteromix shows 100% positive response in early trials for colorectal cancer. Experts say more trials are needed before it can be widely available.
Russian Vaccine ‘Enteromix’ Shows Hope Against Colorectal Cancer
A medical breakthrough from Russia has caught global attention. Scientists have developed a vaccine named Enteromix, which has shown promising results in early human trials for treating colorectal cancer. This type of cancer starts in the colon or rectum, both vital in processing waste.
In the small Phase I trial of about 48 volunteers, every patient responded positively, tumors stopped growing or shrank, and no serious side effects were reported. However, experts caution that these results are early and much larger studies are needed.
Enteromix uses advanced mRNA technology, similar to some COVID-19 vaccines, to train the immune system to attack cancer cells. It is also personalized designed for each patient’s tumor profile, making treatment more precise and targeted.
The vaccine is being developed by Russia’s National Medical Research Radiological Centre and the Engelhardt Institute of Molecular Biology. Their work builds on years of cancer research and the global progress in vaccine science during the COVID-19 pandemic.
Experts remain cautious. Dr. David James Pinato from Imperial College London and Dr. Manikandan Venkatasubramaniyan from India both emphasized the need for larger Phase II and III trials before the vaccine can be widely available.
Reports suggest Enteromix could cost around ?2.5 lakh per dose in Russia, though it may be provided free to citizens once approved. In India, final pricing would depend on subsidies and government programs.
While still in early stages, Enteromix brings new hope for colorectal cancer patients worldwide. The world now waits for further trials with cautious optimism.
